Founded in 1994, Luye Life Sciences Group operates across four key sectors: pharmaceuticals, vaccines, healthcare services, and diagnostics, with a product and service network that spans over 80 countries and regions. The Group focuses on central nervous system (CNS) disorders, oncology, cardiovascular diseases, and viral and pathogenic infections. 

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing, and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, and hosts one of China's National Key Laboratories for Advanced Drug Delivery and Release Systems. Luye Pharma maintains high-level international standards in novel drug delivery technologies, including microspheres, liposomes, and transdermal systems. The company has achieved multiple innovations in new chemical entities and antibodies, while also actively exploring cell and gene therapies. Additionally, it has built platforms for nucleic acid drug development and nano-liposome delivery. The company operates eight production facilities globally with over 30 manufacturing lines, and has launched more than 30 products.

As a leader in oncology in China and an emerging contender for a top place in the global CNS market, Luye Pharma has received approval for 16 innovative products in multiple global markets since 2021. Among these, Rykindo® and Erzofri® received FDA approval, marking a milestone as Rykindo® became the first innovative CNS drug developed by a Chinese company to be approved for the U.S. market.

Luye Pharma has been publicly listed on the Hong Kong Stock Exchange since 2014 (02186.HK), and its subsidiary, Boan Biotech, was listed on the main board of HKEX in 2022 (6955.HK). Boan Biotech currently has three products approved and launched, along with a robust pipeline of innovative antibodies and biosimilars.

Patronus Biotech, the Group's vaccine division, is a global leader and the only company in China offering a U-VLP^TM (Universal Virus-Like Particle) vaccine platform, which overcomes the limitations of pathogen-specific VLP vaccines. Leveraging this breakthrough, Patronus Biotech has developed a high-potential pipeline that includes vaccine candidates for shingles, RSV, malaria, and tuberculosis. The company boasts a team of outstanding experts and operates an internationally accredited facility with pilot and commercial workshops capable of producing 1 billion doses annually. 

Luye Medical owns nearly 30 healthcare facilities across the Asia-Pacific region, including Aurora, the largest mental health service provider in Australia. Luye Medical aims to be a leader in high-growth specialties such as mental health and rehabilitation by delivering innovative, value-based care. Luye Diagnostics, a global leader in automated molecular diagnostics solutions, provides diagnostic products and technological services to customers worldwide, backed by comprehensive sales, operational, and support capabilities.

Committed to a patient-centered approach across its four business sectors, Luye Life Sciences Group offers innovative products, technologies, and services with meaningful clinical value to address needs in its core therapeutic areas including CNS disorders, oncology, cardiovascular diseases, and viral and pathogenic infections. The Group has been named among the “Top 15 Chinese Pharmaceutical Companies”, “Top 10 Innovative Pharma Companies of the Year”, and “Top 5 Companies by the Chinese Pharmaceutical Enterprises R&D Index”. It has also been honored as a “Model Company in Pharmaceutical Innovation for the 70th Anniversary of the P.R.C.” and an “Outstanding Achiever in International Development During the 13th Five-Year Plan”.